Abiopharma

Tradeweb Announces Date for First Quarter 2026 Financial Results

P&G to Webcast Discussion of Third Quarter 2025/26 Earnings Results on April 24

Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis

United-Guardian Reports 2025 Financial Results

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

Credo and TE Connectivity Reach Settlement in Active Electrical Cable Disputes

Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures

Stratus Properties Inc. Reports Year Ended December 31, 2025 Results

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Jeffs Brands: KeepZone AI Enters into Agent Agreement with Skyline Software Systems to Offer 3D Geospatial Visualization Solutions to Global Security Markets